{"nctId":"NCT01392677","briefTitle":"Evaluation of Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Background Combination of Metformin and Sulfonylurea","startDateStruct":{"date":"2011-10"},"conditions":["Type 2 Diabetes Mellitus","High HbA1c Level","Inadequate Glycaemic Control"],"count":311,"armGroups":[{"label":"Dapagliflozin 10 mg tablet","type":"EXPERIMENTAL","interventionNames":["Drug: dapagliflozin"]},{"label":"matching placebo tablet","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: placebo"]}],"interventions":[{"name":"dapagliflozin","otherNames":[]},{"name":"placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Type 2 diabetes mellitus\n* Men or women age ≥ 18 years old\n* Stable dose combination of metformin and sulfonylurea\n* HbA1c ≥7.7% and ≤11.0%\n\nExclusion Criteria:\n\n* Type 1 diabetes mellitus or diabetes insipidus\n* Recent cardiovascular events\n* Kidney or urological disorders\n* Hepatic disorders","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Adjusted Mean Change From Baseline in HbA1c Levels","description":"To compare the change from baseline in HbA1c to week 24 between dapagliflozin 10 mg in combination with metformin and sulfonylurea and placebo in combination with metformin and sulfonylurea.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.17","spread":null},{"groupId":"OG001","value":"-0.86","spread":null}]}]}]},{"type":"SECONDARY","title":"Adjusted Mean Change From Baseline in FPG","description":"To compare the change from baseline in fasting plasma glucose (FPG) to week 24 (LOCF) between dapagliflozin and placebo","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.78","spread":null},{"groupId":"OG001","value":"-34.23","spread":null}]}]}]},{"type":"SECONDARY","title":"Adjusted Mean Change From Baseline in Total Body Weight","description":"To compare the change from baseline in total body weight to week 24 (LOCF) between dapagliflozin and placebo","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.58","spread":null},{"groupId":"OG001","value":"-2.65","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Participants With HbA1c Value < 7.0% at Week 24 (LOCF)","description":"To compare the proportion of subjects achieving a therapeutic glycemic response, defined as HbA1c \\<7.0%, at week 24 (LOCF) between dapagliflozin and placebo","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.1","spread":null},{"groupId":"OG001","value":"31.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Adjusted Mean Change From Baseline in Seated Systolic Blood Pressure","description":"To compare the change from baseline in seated systolic blood pressure (SBP) to week 8 (LOCF) between dapagliflozin and placebo","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.27","spread":null},{"groupId":"OG001","value":"-4.04","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":6,"n":109},"commonTop":["urinary tract infection"]}}}